Novo Nordisk A/S: FDA Discloses Focus of Advisory Committee

Novo Nordisk A/S: FDA Discloses Focus of Advisory Committee Meeting
on Insulin Degludec and Insulin Degludec/Insulin Aspart 
BAGSVAERD, DENMARK -- (Marketwire) -- 10/25/12 --  
Company announcement No 68 / 2012: 
http://hugin.info/2013/R/1652555/533479.pdf 


 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1652555] 
Further information:
Media:
Mike Rulis
Tel: (+45) 3079 3573
mike@novonordisk.com 
In North America:
Ambre Morley
Tel: (+1) 609 216 5240
abmo@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard
Tel: (+1) 609 786 4575
jlis@novonordisk.com
 
 
Press spacebar to pause and continue. Press esc to stop.